Compare Check Point Software Technologies Ltd (CHKP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Incyte Corporation — how do they compare? Check Point Software Technologies Ltd trades at $132.07 (market cap $13.97B), while Incyte Corporation trades at $115.26 (market cap $22.95B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | INCY | |
|---|---|---|
Market Cap | $13.97B | $22.95B |
Sector | Technology | Health |
52-Week High | $223.00 | $118.52 |
52-Week Low | $112.47 | $67.38 |
Enterprise Value | $13.17B | $18.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
